Evidence map›Paper›PMID 38671297›Full record

ArticleAnnals of hematology2024

Analysis of mutation profiles in extranodal NK/T-cell lymphoma: clinical and prognostic correlations.

Yu-Cheng Chang, Hui-Jen Tsai, To-Yu Huang, Nai-Wen Su, Ying-Wen Su, Yi-Fang Chang, Caleb Gon-Shen Chen, Johnson Lin, Ming-Chih Chang, Shu-Jen Chen and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of hematology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Epstein-Barr Virus-Associated T/NK-Cell Neoplasms.Journal of medical virology · 2026
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 1 country.

Yu-Cheng Chang *Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei, Taiwan.ORCID http://orcid.org/0009-0000-1760-2719
Hui-Jen Tsai *National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan.
To-Yu HuangLaboratory of Good Clinical Research Center, Department of Medical Research, MacKay Memorial Hospital, Tamsui District, New Taipei City, Taiwan.
Nai-Wen SuDivision of Hematology and Oncology, Department of Internal Medicine, MacKay Memorial Hospital, No. 92, Section 2, Zhongshan North Road, New Taipei City, 10449, Taiwan.
Ying-Wen SuDivision of Hematology and Oncology, Department of Internal Medicine, MacKay Memorial Hospital, No. 92, Section 2, Zhongshan North Road, New Taipei City, 10449, Taiwan.
Yi-Fang ChangDivision of Hematology and Oncology, Department of Internal Medicine, MacKay Memorial Hospital, No. 92, Section 2, Zhongshan North Road, New Taipei City, 10449, Taiwan.
Caleb Gon-Shen ChenDivision of Hematology and Oncology, Department of Internal Medicine, MacKay Memorial Hospital, No. 92, Section 2, Zhongshan North Road, New Taipei City, 10449, Taiwan.
Johnson LinDivision of Hematology and Oncology, Department of Internal Medicine, MacKay Memorial Hospital, No. 92, Section 2, Zhongshan North Road, New Taipei City, 10449, Taiwan.
Ming-Chih ChangDivision of Hematology and Oncology, Department of Internal Medicine, MacKay Memorial Hospital, No. 92, Section 2, Zhongshan North Road, New Taipei City, 10449, Taiwan.
Shu-Jen ChenACT Genomics Co., Ltd, Taipei, Taiwan.
Hua-Chien ChenACT Genomics Co., Ltd, Taipei, Taiwan.
Ken-Hong LimDivision of Hematology and Oncology, Department of Internal Medicine, MacKay Memorial Hospital, No. 92, Section 2, Zhongshan North Road, New Taipei City, 10449, Taiwan. limkenhong@gmail.com.
Kung-Chao ChangDepartment of Pathology, College of Medicine, National Cheng Kung University Hospital, National Cheng Kung University, Tainan, Taiwan. changkc@mail.ncku.edu.tw.
Sung-Hsin KuoGraduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei, Taiwan. shkuo101@ntu.edu.tw.
Mackay Memorial Hospital · TWNational Taiwan University · TWGenomics Research Center, Academia Sinica · TWNational Cheng Kung University Hospital · TWNational Health Research Institutes · TWNational Tsing Hua University · TW

Funding

Mackay Memorial Hospital MMH-110-75 and MMH-111-70National Science and Technology Council NSTC 111-2314-B195-007
6 · The paper itself

Abstract

The molecular pathogenesis of extranodal NK/T-cell lymphoma (NKTCL) remains obscured despite the next-generation sequencing (NGS) studies explored on ever larger cohorts in the last decade. We addressed the highly variable mutation frequencies reported among previous studies with comprehensive amplicon coverage and enhanced sequencing depth to achieve higher genomic resolution for novel genetic discovery and comparative mutational profiling of the oncogenesis of NKTCL. Targeted exome sequencing was conducted to interrogate 415 cancer-related genes in a cohort of 36 patients with NKTCL, and a total of 548 single nucleotide variants (SNVs) and 600 Copy number variances (CNVs) were identified. Recurrent amplification of the MCL1 (67%) and PIM1 (56%) genes was detected in a dominant majority of patients in our cohort. Functional mapping of genetic aberrations revealed that an enrichment of mutations in the JAK-STAT signaling pathway, including the cytokine receptor LIFR (copy number loss) upstream of JAK3, STAT3 (activating SNVs), and downstream effectors of MYC, PIM1 and MCL1 (copy number gains). RNA in situ hybridization showed the significant consistence of MCL1 RNA level and copy number of MCL1 gene. We further correlated molecular and clinical parameters with overall survival (OS) of these patients. When correlations were analyzed by univariate followed by multivariate modelling, only copy number loss of LIFR gene and stage (III-IV) were independent prognostic factors of reduced OS. Our findings identified that novel loss of LIFR gene significantly correlated with the adverse clinical outcome of NKTCL patients and provided therapeutic opportunities for this disease through manipulating LIFR.

Indexed as

Lymphoma, Extranodal NK-T-CellMutationAdultAgedDNA Copy Number VariationsFemaleHumansMaleMiddle AgedPrognosisClinical and prognostic correlationEpstein Barr virusMolecular biologyNext generation sequencingNK/T cell lymphoma

Identifiers

PMID38671297
OpenAlexW4395693921

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.